Phase IV Trials Are Inadequate Response To HCV Drug Concerns – FDA Cmte.
Skepticism over the utility of Phase IV commitments shaped an FDA advisory committee's recommendations on development of new hepatitis C treatments
You may also be interested in...
FDA should have the authority to sanction pharmaceutical manufacturers that are not adequately fulfilling their post-marketing commitments, the HHS Office of Inspector General suggests
Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.